• linkedin
  • Increase Font
  • Sharebar

    Reformulate, remonetize — and let the patient beware


    David StanleyDavid StaneyThe medical assistant was waiting on the line. I had never heard of the drug she was phoning in, and I wanted to make sure it was something I could order. Unfortunately, it was.

    “Why would anyone write for that?” The words slipped out of my mouth when I realized that Cambia, the mystery med, was simply powdered diclofenac — and that a drug selling for less than $20 in tablet form would bring its manufacturer more than $400 when left as a powder.

    I had momentarily forgotten the medical assistant was still there.

    “It’s what the doctor prescribed,” she said coldly. To which I replied, “I hope the patient has good insurance,” and let her go.

    “Or stupid insurance,” I thought to myself.

    Simple vs. $$$

    Setting aside the fact that diclofenac is what Pharmacist’s Letter calls a “three-strikes” NSAID, more toxic to the liver, cardiovascular, and gastrointestinal systems than other meds in its class, why would a doctor think the theoretical benefit of a few minutes’ faster absorption worth several hundred dollars, when the simple alternative of liquid ibuprofen is available?

    Most of us would come up with a similar answer to that question: Because those hundreds of dollars are someone else’s money, and “simple” is not a word that’s in fashion in today’s medical world.

    At first I felt bad about my slip of the tongue, but the more I thought about it, the less remorseful I felt.

    An entire ecosystem

    We all know there exists an entire sub-industry of incredibly overpriced pharmaceutical products that contribute nothing to the advancement of medicine.

    There’s Duexis — nothing but ibuprofen combined with famotidine. Or Solodyn — a strength of minocycline just different enough that it can’t be substituted for the generic that costs hundreds of dollars less. Or Treximet — simply sumatriptan and naproxen.

    The list goes on and on, and there seems to be a new addition every week. It’s an entire economic ecosystem that depends on pulling the wool over the eyes of prescribers.

    Well it’s time their eyes were opened, and stereotypical pharmacists — those polite, quiet, sheepish professionals who hold their tongues unless spoken to — are not going to get that job done.

    David Stanley, RPh
    David Stanley is a pharmacy owner, blogger, and professional writer in northern California. Contact him at [email protected]


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available